[O-43] Oral Session 43

[O-43-1] naPPA: symptoms/prognosis, and the CBF/ dopamine transporter scintigraphy

^○Mika Otsuki¹, Yoshitsugu Nakagawa², Shuichi Koshimizu³, Akihiko Ogata³, Kazuyoshi Shinpo³, Yasunori Mito⁴, Yasutaka Tajima⁴, Shinsuke Hamada⁵, Shigehisa Ura⁶, Kimito Kondo⁷, Hideki Houzen⁸, Ikuko Takahashi-iwata⁹, Masaaki Matsushima⁹, Ichiro Yabe⁹ (1.Faculty of Health Sciences, Hokkaido University Graduate School of Health Sciences, Japan, 2.School of Rehabilitation Sciences, Health Sciences University of Hokkaido, 3.Hokkaido Surgical Memorial Hospital, Division of Neurology, 4.Sapporo General Hospital, Division of Neurology, 5.Hokuyukai Neurological Hospital, 6.Japanese Red Cross Asahikawa Hospital, Division of Neurology, 7.Department of Neurology, Hokuto Hospital, 8.Department of Neurology, Obihiro Kosei Hospital, 9.Department of Neurology, Hokkaido University Graduate School of Medicine)